Bernstein has adjusted its outlook for Revvity (RVTY, Financial), reducing the company's price target from $140 to $120 while maintaining a Market Perform rating. This revision reflects ongoing challenges in the health sector, particularly surrounding tariffs, potential issues with National Institutes of Health (NIH) funding, and broader concerns regarding academic and government support. Additionally, hits from the Department of Health and Human Services (HHS) to the pharmaceutical industry are affecting expectations.
Initially optimistic about a recovery in the tools market at the start of the year, Bernstein now observes these anticipated risks materializing, leading to a more cautious stance as the first quarter unfolds. These developments underscore the uncertainties facing the sector and the adjustments companies like Revvity may need to navigate moving forward.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 18 analysts, the average target price for Revvity Inc (RVTY, Financial) is $136.27 with a high estimate of $185.00 and a low estimate of $102.00. The average target implies an upside of 42.63% from the current price of $95.54. More detailed estimate data can be found on the Revvity Inc (RVTY) Forecast page.
Based on the consensus recommendation from 21 brokerage firms, Revvity Inc's (RVTY, Financial) average brokerage recommendation is currently 2.2, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for Revvity Inc (RVTY, Financial) in one year is $114.65, suggesting a upside of 20% from the current price of $95.54. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the Revvity Inc (RVTY) Summary page.
